Cargando…

Direct Healthcare Costs Associated with Oligoarticular Juvenile Idiopathic Arthritis at a Single Center

Oligoarticular juvenile idiopathic arthritis (JIA) is a common disease in pediatric rheumatology. The management of oligoarticular JIA can result in a considerable economic burden. This study is a four-year, retrospective cost identification analysis performed to determine the annual direct cost of...

Descripción completa

Detalles Bibliográficos
Autores principales: Thakral, Amit, Pinto, Daniel, Miller, Michael, Curran, Megan L., Klein-Gitelman, Marisa, French, Dustin D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482013/
https://www.ncbi.nlm.nih.gov/pubmed/32952562
http://dx.doi.org/10.1155/2020/5640425
_version_ 1783580724557774848
author Thakral, Amit
Pinto, Daniel
Miller, Michael
Curran, Megan L.
Klein-Gitelman, Marisa
French, Dustin D.
author_facet Thakral, Amit
Pinto, Daniel
Miller, Michael
Curran, Megan L.
Klein-Gitelman, Marisa
French, Dustin D.
author_sort Thakral, Amit
collection PubMed
description Oligoarticular juvenile idiopathic arthritis (JIA) is a common disease in pediatric rheumatology. The management of oligoarticular JIA can result in a considerable economic burden. This study is a four-year, retrospective cost identification analysis performed to determine the annual direct cost of care for patients with oligoarticular JIA and possible predictive clinical factors. Direct healthcare costs were defined as those associated with office visits, laboratory studies, hospital admissions, joint injections, medications, infusions, radiology tests, and emergency room visits. Disease characteristics and patient information included ANA status, gender, age at diagnosis, duration from diagnosis to initial visit during the study period, and whether uveitis had been diagnosed. We identified 97 patients with oligoarticular JIA eligible for the study. The median age of diagnosis was 4.3 years. Positive ANA were noted in 75% of patients. 34% of patients received at least one intra-articular steroid injection. 32% of patients were prescribed a biologic during the study period, predominantly with other medications, while 23% of patients received only NSAIDs. 20% of patients were prescribed oral steroids. The average total direct medical cost in this study per year for an oligoarticular JIA patient was $3929 ± 6985. Medications accounted for 85% of annual direct medical costs. Clinic visits and laboratory testing accounted for 8% and 5%, respectively. Patient characteristics and demographics were tested for association with direct medical costs by the Wilcoxon rank sum test and Kruskal-Wallis test. Patients who were ANA positive had increased annual costs compared to patients who are ANA negative. ANA-positive patients were found to have statistically significant costs, particularly, in laboratory tests, procedural costs, radiology costs, and medication costs. The results reported here provide information when allocating healthcare resources and a better understanding of the economic impact oligoarticular JIA has on the United States healthcare system.
format Online
Article
Text
id pubmed-7482013
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-74820132020-09-18 Direct Healthcare Costs Associated with Oligoarticular Juvenile Idiopathic Arthritis at a Single Center Thakral, Amit Pinto, Daniel Miller, Michael Curran, Megan L. Klein-Gitelman, Marisa French, Dustin D. Int J Rheumatol Research Article Oligoarticular juvenile idiopathic arthritis (JIA) is a common disease in pediatric rheumatology. The management of oligoarticular JIA can result in a considerable economic burden. This study is a four-year, retrospective cost identification analysis performed to determine the annual direct cost of care for patients with oligoarticular JIA and possible predictive clinical factors. Direct healthcare costs were defined as those associated with office visits, laboratory studies, hospital admissions, joint injections, medications, infusions, radiology tests, and emergency room visits. Disease characteristics and patient information included ANA status, gender, age at diagnosis, duration from diagnosis to initial visit during the study period, and whether uveitis had been diagnosed. We identified 97 patients with oligoarticular JIA eligible for the study. The median age of diagnosis was 4.3 years. Positive ANA were noted in 75% of patients. 34% of patients received at least one intra-articular steroid injection. 32% of patients were prescribed a biologic during the study period, predominantly with other medications, while 23% of patients received only NSAIDs. 20% of patients were prescribed oral steroids. The average total direct medical cost in this study per year for an oligoarticular JIA patient was $3929 ± 6985. Medications accounted for 85% of annual direct medical costs. Clinic visits and laboratory testing accounted for 8% and 5%, respectively. Patient characteristics and demographics were tested for association with direct medical costs by the Wilcoxon rank sum test and Kruskal-Wallis test. Patients who were ANA positive had increased annual costs compared to patients who are ANA negative. ANA-positive patients were found to have statistically significant costs, particularly, in laboratory tests, procedural costs, radiology costs, and medication costs. The results reported here provide information when allocating healthcare resources and a better understanding of the economic impact oligoarticular JIA has on the United States healthcare system. Hindawi 2020-09-01 /pmc/articles/PMC7482013/ /pubmed/32952562 http://dx.doi.org/10.1155/2020/5640425 Text en Copyright © 2020 Amit Thakral et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Thakral, Amit
Pinto, Daniel
Miller, Michael
Curran, Megan L.
Klein-Gitelman, Marisa
French, Dustin D.
Direct Healthcare Costs Associated with Oligoarticular Juvenile Idiopathic Arthritis at a Single Center
title Direct Healthcare Costs Associated with Oligoarticular Juvenile Idiopathic Arthritis at a Single Center
title_full Direct Healthcare Costs Associated with Oligoarticular Juvenile Idiopathic Arthritis at a Single Center
title_fullStr Direct Healthcare Costs Associated with Oligoarticular Juvenile Idiopathic Arthritis at a Single Center
title_full_unstemmed Direct Healthcare Costs Associated with Oligoarticular Juvenile Idiopathic Arthritis at a Single Center
title_short Direct Healthcare Costs Associated with Oligoarticular Juvenile Idiopathic Arthritis at a Single Center
title_sort direct healthcare costs associated with oligoarticular juvenile idiopathic arthritis at a single center
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482013/
https://www.ncbi.nlm.nih.gov/pubmed/32952562
http://dx.doi.org/10.1155/2020/5640425
work_keys_str_mv AT thakralamit directhealthcarecostsassociatedwitholigoarticularjuvenileidiopathicarthritisatasinglecenter
AT pintodaniel directhealthcarecostsassociatedwitholigoarticularjuvenileidiopathicarthritisatasinglecenter
AT millermichael directhealthcarecostsassociatedwitholigoarticularjuvenileidiopathicarthritisatasinglecenter
AT curranmeganl directhealthcarecostsassociatedwitholigoarticularjuvenileidiopathicarthritisatasinglecenter
AT kleingitelmanmarisa directhealthcarecostsassociatedwitholigoarticularjuvenileidiopathicarthritisatasinglecenter
AT frenchdustind directhealthcarecostsassociatedwitholigoarticularjuvenileidiopathicarthritisatasinglecenter